Skip to main content

Table 2 Treatment Related Adverse Events occurring in > 10% of subjects OR ≥ grade 3

From: Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Adverse events

Grade 1–2

Grade 3

Grade 4

Fatigue

23 (65.7%)

1 (2.9%)

 

Nausea

20 (57.1%)

  

Anorexia

11 (31.4%)

  

Vomiting

11

1

 

Edema

10 (28.6%)

  

Anemia

8 (22.9%)

1

 

Diarrhea

8

  

Rash

8

1

 

Shortness of breath

7 (20%)

  

Constipation

5 (14.3%)

  

Thrombocytopenia

4 (11.4%)

  

Fever

 

1

 

Hypoglycemia

 

1

Â